PDCD1 and neoplasm: Objective radiographic responses were observed in 53% of patients, and complete responses were achieved in 21% of patients, indicating that a mismatch repair-deficiency can make the tumor sensitive to PD-1 blockade, regardless of the cancers’ tissue of origin.